167 related articles for article (PubMed ID: 3910223)
1. High dose cisplatin and high dose carboplatin in refractory ovarian cancer.
Ozols RF; Behrens BC; Ostchega Y; Young RC
Cancer Treat Rev; 1985 Sep; 12 Suppl A():59-65. PubMed ID: 3910223
[TBL] [Abstract][Full Text] [Related]
2. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
Vermorken JB
Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin.
Mangioni C; Bolis G; Pecorelli S; Bragman K; Epis A; Favalli G; Gambino A; Landoni F; Presti M; Torri W
J Natl Cancer Inst; 1989 Oct; 81(19):1464-71. PubMed ID: 2674459
[TBL] [Abstract][Full Text] [Related]
5. High-dose cisplatin therapy in ovarian cancer.
Ozols RF; Young RC
Semin Oncol; 1985 Dec; 12(4 Suppl 6):21-30. PubMed ID: 3909419
[TBL] [Abstract][Full Text] [Related]
6. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
[TBL] [Abstract][Full Text] [Related]
8. High-dose carboplatin in refractory ovarian cancer patients.
Ozols RF; Ostchega Y; Curt G; Young RC
J Clin Oncol; 1987 Feb; 5(2):197-201. PubMed ID: 3543243
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
10. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease.
Lund B; Hansen M; Hansen OP; Hansen HH
J Clin Oncol; 1989 Oct; 7(10):1469-73. PubMed ID: 2674334
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy.
Speyer JL; Beller U; Colombo N; Sorich J; Wernz JC; Hochster H; Green M; Porges R; Muggia FM; Canetta R
J Clin Oncol; 1990 Aug; 8(8):1335-41. PubMed ID: 2199620
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.
Adams M; Kerby IJ; Rocker I; Evans A; Johansen K; Franks CR
Acta Oncol; 1989; 28(1):57-60. PubMed ID: 2650722
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
Evans BD; Raju KS; Calvert AH; Harland SJ; Wiltshaw E
Cancer Treat Rep; 1983 Nov; 67(11):997-1000. PubMed ID: 6315233
[TBL] [Abstract][Full Text] [Related]
16. [Second-generation cisplatin analogs].
Ariyoshi Y; Ota K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1043-50. PubMed ID: 3551846
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin in the treatment of ovarian cancer.
Alberts DS; Mason-Liddil N
Semin Oncol; 1989 Apr; 16(2 Suppl 5):19-26. PubMed ID: 2655095
[TBL] [Abstract][Full Text] [Related]
18. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study.
Weiss G; Green S; Alberts DS; Thigpen JT; Hines HE; Hanson K; Pierce HI; Baker LH; Goodwin JW
Eur J Cancer; 1991; 27(2):135-8. PubMed ID: 1827275
[TBL] [Abstract][Full Text] [Related]
19. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.
Trump DL; Grem JL; Tutsch KD; Willson JK; Simon KJ; Alberti D; Storer B; Tormey DC
J Clin Oncol; 1987 Aug; 5(8):1281-9. PubMed ID: 3040920
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin in the first-line chemotherapy of ovarian cancer.
Alberts DS; Canetta R; Mason-Liddil N
Semin Oncol; 1990 Feb; 17(1 Suppl 2):54-60. PubMed ID: 2406922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
